Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

Myotonic Dystrophy 1 Clinical Trial

Official title:

A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02858908
• Other study ID #: AMO-02-MD-2-001
• Secondary ID: 2016-000067-16
• Status: Completed
• Phase: Phase 2
• Start date: July 20, 2016
• Est. completion date: January 2018

Study information

• Verified date: December 2018
• Source: AMO Pharma Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy. The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: January 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 45 Years

Eligibility

Inclusion Criteria:

• Adolescents or adults with diagnosis of congenital or juvenile-onset type 1 myotonic dystrophy (DM-1)

• Diagnosis must be genetically confirmed

• Subjects must be male or female aged 12 years to 45 years

• Subjects must have a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening and Run-in (V2)

• Subjects must be ambulatory and able to complete the 10 metre walk/run test (splints allowed)

• Subject's legally authorized representative (LAR) must provide written informed consent and there must be written consent or assent (as age applicable and developmentally appropriate) by the subject before any study-related procedures are conducted

Exclusion Criteria:

• Non-ambulatory (full time) wheel chair user

• Receiving stimulant medication

• Receiving other medications/therapies not stable (changed) within 4 weeks prior to Run-in (V2)

• Medical illness or other concern which would cause investigator to conclude subjects will not be able to perform the study procedures or assessments or would confound interpretation of data obtained during assessment.

• Current enrolment in a clinical trial of an investigational drug or enrolment in a clinical trial of an investigational drug in the last 6 months

• Women of child bearing potential who are pregnant, lactating or not willing to use a protocol defined acceptable contraception method if sexually active and not surgically sterile.

• Gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the study medication and impact the interpretability of the study results

• Current clinically significant (as determined by the investigator) cardiovascular, renal, hepatic, endocrine or respiratory disease

• Clinically significant heart disease (in the opinion of the investigator) or second or third degree heart block, atrial flutter, atrial fibrillation, ventricular arrhythmias, or is receiving medication for treatment of a cardiac arrhythmia

• A history of chronic liver disease with current out of range values for Alanine transaminase (ALT), clinically relevant hepatic steatosis or other clinical manifestations of ongoing liver disease

• A history of significant drug allergy (such as Steven-Johnson syndrome, anaphylaxis)

• A history of alcohol or substance use disorders

Related Conditions & MeSH terms

• Myotonic Dystrophy
• Myotonic Dystrophy 1

Intervention

Drug:
• Tideglusib
Tideglusib for oral suspension,

Locations

Country	Name	City	State
United Kingdom	Newcastle-upon-Tyne Hospitals NHS Trust	Newcastle Upon Tyne	Tyne And Wear

Sponsors (1)

Lead Sponsor	Collaborator
AMO Pharma Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse events (AEs), including serious adverse events (SAEs), between baseline to end of study.	Adverse events may be volunteered spontaneously by the subject, or discovered as a result of general, non-leading questioning by physician.	14 weeks (baseline through end of study)